Several other research analysts have also issued reports on KALA. JPMorgan Chase & Co. set a $35.00 price target on Kala Pharmaceuticals and gave the stock a buy rating in a research report on Sunday, November 19th. Wedbush restated an outperform rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. BidaskClub upgraded Kala Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, December 29th. Finally, Zacks Investment Research lowered Kala Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $36.80.
Kala Pharmaceuticals (KALA) traded up $1.35 during trading hours on Friday, hitting $13.61. The stock had a trading volume of 1,113,400 shares, compared to its average volume of 973,460. Kala Pharmaceuticals has a 1-year low of $11.81 and a 1-year high of $26.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00. The company has a market cap of $329.73 and a price-to-earnings ratio of -7.48.
A number of hedge funds have recently bought and sold shares of KALA. Victory Capital Management Inc. bought a new position in Kala Pharmaceuticals during the third quarter worth about $12,414,000. Bank of New York Mellon Corp bought a new position in Kala Pharmaceuticals during the third quarter worth about $540,000. Commonwealth Equity Services Inc bought a new position in Kala Pharmaceuticals during the third quarter worth about $360,000. EAM Investors LLC bought a new position in Kala Pharmaceuticals during the third quarter worth about $1,353,000. Finally, American International Group Inc. bought a new position in Kala Pharmaceuticals during the third quarter worth about $122,000. Hedge funds and other institutional investors own 62.96% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was reported by Markets Daily and is the property of of Markets Daily. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2018/01/09/wells-fargo-co-reaffirms-buy-rating-for-kala-pharmaceuticals-kala.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.